ArticleBMC nephrology2025
INHBA knockdown inhibits renal fibrosis in mice following ischemia-reperfusion injury by suppressing activation of the TGF-β/Smad signaling pathway.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Review
- OptiSyn: an interpretable, multi-omics-driven graph convolutional network framework for synergy-oriented drug combination design in disease treatment.Chinese medicine · 2026Article
- Identification of prognostic genes associated with tolerogenic dendritic cells in gastric cancer based on transcriptomic data.PloS one · 2026Article
- Spinal cord injury-induced overflow incontinence reshapes the activin-follistatin-inhibin axis in mouse bladder and kidney.Frontiers in molecular biosciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute kidney injury (AKI) and renal fibrosis are clinical conditions associated with high morbidity and mortality. Renal ischemia-reperfusion (I/R) injury is a major cause of AKI.
objectiveThis study aimed to investigate the role of inhibin subunit beta A (INHBA) in the pathogenesis of renal fibrosis and the underlying mechanisms during I/R-induced kidney injury using an in vivo model.
methodsA mouse model of renal I/R injury was established. INHBA function was evaluated by intrarenal injection of INHBA-short hairpin RNA (INHBA-shRNA) on day 7 after I/R. Renal function, tubular damage, and interstitial fibrosis were assessed using detection kits, hematoxylin-eosin staining, and Masson's trichrome staining. reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and Western blot analyses were performed to examine the expression of fibrosis-related genes, including fibronectin (FN), collagen I (Col-I), and alpha-smooth muscle actin (α-SMA). Additionally, RT-qPCR, Western blot, and immunohistochemistry were used to determine INHBA expression in different groups. Transforming growth factor beta 1 (TGF-β1) levels in kidney tissue were measured by enzyme-linked immunosorbent assay. The effect of INHBA-shRNA on the TGF-β/Smad signaling pathway was analyzed by Western blot.
resultsINHBA-shRNA significantly reduced INHBA expression, serum creatinine levels, 24-hour urinary albumin, and urinary albumin-to-creatinine ratio in I/R-injured mice. It also alleviated renal tubular damage and interstitial fibrosis. Furthermore, INHBA knockdown downregulated the expression of fibrosis markers, inhibited TGF-β1 secretion, and suppressed activation of the TGF-β/Smad signaling pathway, as evidenced by reduced expression of FN, Col-I, α-SMA, phosphorylated Smad2, and phosphorylated Smad3.
conclusionKnockdown of INHBA attenuates renal fibrosis after I/R injury in mice by suppressing activation of the TGF-β/Smad signaling pathway. This pathway may represent a potential therapeutic target for renal I/R injury.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.